This site is intended for health professionals only

At the heart of general practice since 1960

pul jul aug2020 cover 80x101px
Read the latest issue online

Independents' Day

NICE puts drug assessment review on hold

NICE has put plans to revamp its drug evaluation methodology on hold, the clinical watchdog has announced.

NICE chiefs said more work was needed before the institute could implement any new ‘value-based’ assessments, which will take into account the relative societal benefits of a drug, following a consultation on the potential changes.

The DH outlined plans in 2012 to take NICE’s ‘rationing’ role away altogether, but has since backtracked and last year confirmed the institute would continue to have full responsibility for decisions on new drugs – but with a new remit to take into account the relative societal benefits of a drug, for example whether it can impact on carer or employment costs, or treat a particularly severe condition.

However, the NICE board of directors said it found no agreement among stakeholder responses to a three-month consultation on the proposed new framework, and has decided a wider review is needed.

NICE chief executive Sir Andrew Dillon said: ‘We’ve been looking in detail at how to change the way we appraise medicines and other technologies on behalf of the NHS. Following an exhaustive consultation, it’s clear that just changing NICE’s methods will not overcome concerns about how the NHS accesses new treatments.

‘We also need to look at the other processes, including the model of pharmaceutical research and development, the expectations that companies and patient groups have about how risk and reward is shared between the industry and a publicly funded NHS, and in the arrangements for commissioning expensive new treatments.’

>>>> Clinical Newswire

Readers' comments (1)

  • Vinci Ho

    The philosophy of NICE certainly needs modification to keep in line with time and circumstances . On one hand, it must not become the puppet of a government to blindly cut cost in the expense of patients' prognosis , it also has to be realistic about what is affordable as far as NHS is concerned . The definition of cost effectiveness or value for money is so often arbitrary or he-say by politicians of policy makers.
    I think NICE should change its name to I-NICE: Independent- National Institute of Clinical Excellence .
    ( just love the word independent at the moment, good luck , Scotties!)

    Unsuitable or offensive? Report this comment

Have your say